Cancer cells can develop resistance to therapies, making treatment challenging. Understanding resistance mechanisms is crucial for developing next-generation drugs. For example, secondary mutations in the EGFR gene can confer resistance to first-generation inhibitors, necessitating the development of newer inhibitors like osimertinib.
